Thermo Fisher microbiology business Acquired by Astorg | Healthcare M&A Deal

Astorg has acquired the Thermo Fisher microbiology business, a diagnostics imaging business in the healthcare sector, for $1.08 billion. The divestiture acquisition covers antimicrobial susceptibility testing and culture media, plus collection and transport systems, instruments, and consumables used to detect pathogens in clinical specimens and support quality control. Thermo Fisher microbiology sales were about $645 million, and Astorg acquisitions aim to scale the platform with a focus on operational performance and growth. Astorg acquisitions are structured as a private equity acquisition with cash consideration and a $50 million seller note, and the deal is expected to close in the second half of the year as a healthcare M&A divestiture acquisition.